Search research articles
Contact Us
Filters
Showing results (861-870 of 875) with videos related to
Page
of 88
Sort By:
The American Journal of Emergency Medicine
|
November 1, 1996
Research directions in emergency medicine
R V Aghababian, W G Barsan, W H Bickell, et al.
Journal of Medicinal Chemistry
|
March 13, 2024
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein
John M Ketcham, Stephen J Harwood, Ruth Aranda, et al.
ACS Medicinal Chemistry Letters
|
January 8, 2019
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity
Jay B Fell, John P Fischer, Brian R Baer, et al.
Nature Communications
|
August 11, 2022
SARS-CoV-2 and other respiratory pathogens are detected in continuous air samples from congregate settings
Mitchell D Ramuta, Christina M Newman, Savannah F Brakefield, et al.
Medrxiv : the Preprint Server for Health Sciences
|
April 5, 2022
SARS-CoV-2 and other respiratory pathogens are detected in continuous air samples from congregate settings
Mitchell D Ramuta, Christina M Newman, Savannah F Brakefield, et al.
Molecular Cancer Therapeutics
|
June 21, 2024
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos, et al.
Cancer Discovery
|
August 8, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer
Lars D Engstrom, Ruth Aranda, Laura Waters, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 10, 2013
Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors
Joel T Arcari, Jean S Beebe, Martin A Berliner, et al.
Cancer Discovery
|
October 30, 2019
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin, Lars D Engstrom, Lauren Hargis, et al.
Journal of Medicinal Chemistry
|
April 7, 2020
Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of Cancer
Jay B Fell, John P Fischer, Brian R Baer, et al.
Page
of 88
Search research articles
Search
Showing results (861-870 of 875) with videos related to
Sort By:
Page
of 88
The American Journal of Emergency Medicine
|
November 1, 1996
Research directions in emergency medicine
R V Aghababian, W G Barsan, W H Bickell, et al.
Journal of Medicinal Chemistry
|
March 13, 2024
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein
John M Ketcham, Stephen J Harwood, Ruth Aranda, et al.
ACS Medicinal Chemistry Letters
|
January 8, 2019
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity
Jay B Fell, John P Fischer, Brian R Baer, et al.
Nature Communications
|
August 11, 2022
SARS-CoV-2 and other respiratory pathogens are detected in continuous air samples from congregate settings
Mitchell D Ramuta, Christina M Newman, Savannah F Brakefield, et al.
Medrxiv : the Preprint Server for Health Sciences
|
April 5, 2022
SARS-CoV-2 and other respiratory pathogens are detected in continuous air samples from congregate settings
Mitchell D Ramuta, Christina M Newman, Savannah F Brakefield, et al.
Molecular Cancer Therapeutics
|
June 21, 2024
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading
Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos, et al.
Cancer Discovery
|
August 8, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer
Lars D Engstrom, Ruth Aranda, Laura Waters, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 10, 2013
Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors
Joel T Arcari, Jean S Beebe, Martin A Berliner, et al.
Cancer Discovery
|
October 30, 2019
The KRAS<sup>G12C</sup> Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin, Lars D Engstrom, Lauren Hargis, et al.
Journal of Medicinal Chemistry
|
April 7, 2020
Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of Cancer
Jay B Fell, John P Fischer, Brian R Baer, et al.
Page
of 88